Voya Investment Management LLC Purchases 6,669 Shares of Kymera Therapeutics, Inc. $KYMR

Voya Investment Management LLC boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 22.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,455 shares of the company’s stock after acquiring an additional 6,669 shares during the period. Voya Investment Management LLC’s holdings in Kymera Therapeutics were worth $2,063,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of KYMR. BVF Inc. IL increased its position in shares of Kymera Therapeutics by 6.6% during the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after purchasing an additional 340,909 shares in the last quarter. Siren L.L.C. increased its position in Kymera Therapeutics by 9.1% during the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock valued at $88,687,000 after buying an additional 270,580 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Kymera Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after acquiring an additional 59,347 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after acquiring an additional 491,737 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Kymera Therapeutics by 49.4% during the second quarter. Jennison Associates LLC now owns 825,025 shares of the company’s stock worth $36,004,000 after acquiring an additional 272,739 shares during the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bros. Advisors Lp Baker purchased 2,005,813 shares of Kymera Therapeutics stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $86.00 per share, for a total transaction of $172,499,918.00. Following the completion of the transaction, the director owned 7,955,916 shares in the company, valued at $684,208,776. The trade was a 33.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Nello Mainolfi sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.17, for a total value of $8,917,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares in the company, valued at approximately $58,895,179.94. This represents a 13.15% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 488,585 shares of company stock worth $41,408,199. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Trading Down 2.2%

Shares of NASDAQ KYMR opened at $81.32 on Monday. The company has a 50 day simple moving average of $69.68 and a two-hundred day simple moving average of $55.00. The stock has a market cap of $5.85 billion, a price-to-earnings ratio of -22.65 and a beta of 2.28. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The business had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on KYMR. UBS Group upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Thursday, December 4th. BTIG Research set a $138.00 price target on shares of Kymera Therapeutics in a report on Monday, December 8th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Stephens upped their target price on Kymera Therapeutics from $65.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Kymera Therapeutics has an average rating of “Buy” and a consensus target price of $116.30.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.